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Abstract
Purpose For several years theWorkingGroup Cardiovascular
Nuclear Medicine of the German Society of NuclearMedicine
has been performing a regular survey to obtain information on
technique, utilization and development of myocardial perfu-
sion scintigraphy (MPS). Currently, data of six surveys from
2005 to 2012 are available. The aim of this paper is to deliver a
general and comprehensive overview of all surveys
documenting the course of patient doses over time and the
development of the method.
Methods A one-page questionnaire with number of MPS
patients, number of stress and rest MPS, referral structure
and several technical issues was sent to all centres performing
MPS in Germany and evaluated. With the data on protocol
utilization, effective MPS patient doses were estimated.
Results MPS per million population (pmp) varied between
2,380 and 2,770. In 2012, MPS pmp showed a slight increase
for the first time. From 2005 to 2009 the angiography to MPS
ratio increased from 3.4 to 4.4, and the revascularization to
MPS ratio decreased from 0.66 to 0.53. In 2012, both indices
demonstrated an opposite trend for the first time (4.1 and
0.55). A total of 108 centres participated in all surveys. They
showed an increase in MPS patients of 4.0 % over the
reporting period. In 2012, more than 50 % of the centres
experienced no change or an increase in MPS numbers. The
leading single competitor was MRI, followed by angiography
and stress echocardiography. 201Tl studies have decreased
since 2005 from 20 to 5 %. 99mTc MPS studies showed a mild
increase in 2-day protocols. In 2012, the average effective
dose per patient was estimated at 7.4 mSv. Due to the decreas-
ing use of 201Tl, a mild decline over the observation period can
be documented. Dynamic exercise stress was the most com-
mon stress test and adenosine the leading pharmacological
stress agent, with a growing percentage. In 2012, the
regadenoson percentage was 9 %. Gated single photon emis-
sion computed tomography (SPECT) noted an increasing
acceptance with >70 % in 2012. The segmental scoring of
perfusion studies had a low acceptance. Ambulatory care
cardiologists represented the major referral group.
Conclusion Germany has a moderate to moderate-high MPS
utilization rate. Nevertheless, coronary artery disease (CAD)
diagnosis and disease management are dominated by angiog-
raphy. The survey data reveal a positive trend in MPS and a
decrease in average patient dose reflecting good practice with
guideline adherence, the implementation of technical im-
provements and success in training.
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Introduction
Data on myocardial perfusion scintigraphy (MPS), especially
long-term data about routine use and practice, are of growing
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interest in times of competitive methods, dose reduction ap-
proaches and quality assurance. Thus, for several years, the
Working Group Cardiovascular Nuclear Medicine of the Ger-
man Society of Nuclear Medicine has been performing a
regular survey in order to obtain reliable information on
technique, practice, utilization and development of MPS.
Combining the data on protocol utilization with the German
diagnostic reference levels (DRL, derived from implementa-
tion of the Euratom directive), values of effective patient doses
from MPS can be estimated and monitored over time [1].
With the 2012 inquiry, data of six surveys covering the
reporting years 2005–2009 and 2012 are available. The de-
tailed annual results of private practices, general hospitals and
university hospitals were published elsewhere [2–7]. The aim
of this paper is to deliver a more general and comprehensive
overview of all surveys documenting the development of the
method and the average radiation doses, the latter being of
special interest in the comparison with competitive methods
and measures to reduce patients’ radiation exposure.
Long-term survey data are rare. The European Council of
Nuclear Cardiology (ECNC), a joint organization of the Eu-
ropean Association of Nuclear Medicine (EANM) and the
European Society of Cardiology (ESC), which strives to pro-
mote clinical and professional activity in nuclear cardiology,
published two survey reports on the years 2005 and 2007 [17,
26]. More recently, the American Society of Nuclear Cardiol-
ogy (ASNC) conducted a random sample survey of members
in 2011. Data on the practice of nuclear cardiology were
published in 2012 [8] and on protocols and doses in 2013 [9].
Since Germany is the most populous country in Europe, the
German surveys may reflect to some extent developments in
daily and routine MPS practice in Europe and supplement the
European report data of 2005 and 2007. The course of the
patient numbers is, however, difficult to interpolate to other
countries as national reimbursement regulations have great
impact and may even dilute or delay trends resulting from
evidence-giving studies.
Materials and methods
Survey and data management
Based on the register of members of the Germany Society of
Nuclear Medicine, registers of office-based nuclear medicine
physicians of the 17 state chambers of physicians and the
German hospitals’ address book, potential facilities or physi-
cians practising nuclear medicine were identified and updated
before every survey.
A one-page questionnaire with a cover letter was sent by
fax. In cases of no response a first reminder was forwarded 4
weeks later and a second 4–6 weeks after that.
All questionnaires comprised: (1) number of patients with
MPS, (2) number of stress and rest MPS, (3) stress techniques,
(4) radiopharmaceuticals, (5) protocols, (6) utilization of gated
single photon emission computed tomography (SPECT) and
(7) the referral structure. Since 2007 the frequency of a quan-
titative perfusion analysis has been requested. In 2006, 2007
and 2012 data on change ofMPS utilization, in 2006 and 2009
data on attenuation correction (AC), in 2006 data on indica-
tions [detection of coronary artery disease (CAD)], in 2007
data on diabetics and in 2008 data on age structure were
additionally surveyed.
In order to verify the representativeness of the survey and
to estimate the total or “true” MPS numbers reliably, the
survey results were related to the data of the National Associ-
ation of Statutory Health Insurance Physicians (NASHIP)
[Kassenärztliche Bundesvereinigung (KBV)] [10]. The
NASHIP data represent the official number of ambulatory
statutory health insurance patients.
The estimate of the total MPS numbers was based on the
fact that three groups of MPS patients were not covered by the
NASHIP statistics: (1) privately insured patients, (2) inpa-
tients of hospitals and (3) hospital patients of private practices.
Data concerning the last two items were derived from the
surveys. MPS numbers from private insurance companies
were not available and estimated from the percentage of
privately insured patients documented in the 2007 and 2011
German microcensus. The percentage amounted to 11.8 % in
2007 and to 12.8 % in 2011 (mean 12.4 %) [11, 12]. Based on
these data, a proportion of 12.4 % MPS of privately insured
patients was taken for the missing data concerning item 1 to
determine the true annual MPS numbers.
Accordingly, 50–55 % of all MPS were evaluated with
every query and the true annual MPS patient numbers esti-
mated to be twice as high as the survey patient numbers,
which were therefore multiplied by 2. This approach results
in a slight overestimation of the total MPS number by<10 %.
For utilization calculation the true number of annual MPS
patients was divided by the current population statistics. The
results were related to the angiography numbers of the annual
German report on cardiology [13]. Revascularization case
numbers were also taken from the annual cardiology statistics.
At the time of writing this paper, only cardiology data up to
2011 were available, and they related to the MPS 2012
numbers.
Estimated effective doses
The radiopharmaceutical activities used in the different proto-
cols for effective dose calculation are listed in Table 5. They
are derived from DRL for the most frequent nuclear medicine
studies. DRL were designated by the German Federal Office
for Radiation Protection in 2003, implementing the Council
Directive 97/43 Euratom [14, 15]. DLR represent the average
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radiopharmaceutical activities. Accordingly, in a 2-day proto-
col 2×600 MBq can be applied, whereas in a 1-day protocol
the first injection should amount to 250 MBq and the second
to 750 MBq. Thus, it is also appropriate and dose saving to
inject 2×250 MBq in a 2-day protocol. Additionally, multi-
head SPECT cameras deliver 250 MBq scans with an excel-
lent image quality. In light of these considerations, lower and
upper activity ranges for the average effective dose calcula-
tions of the different protocols were defined (Table 5). For
201Tl an effective dose of 0.22 mSv/MBq was taken and for
99mTc radiopharmaceuticals at stress of 0.008 mSv/MBq and
at rest of 0.009 mSv/MBq [16]. The last two refer to 99mTc-
sestamibi. The effective dose of 99mTc-tetrofosmin is slightly
lower but was equated with 99mTc-sestamibi.
Statistical analysis
Data are presented as numbers and percentage of observation
when appropriate. Statistical analyses for significant changes
in the course of the surveys were performed using the
Kruskal-Wallis test and the chi-square test when appropriate.
For the analyses the statistical software package IBM SPSS,
version 20 (IBM Corp., Armonk, NY, USA) was used. A p
value <0.05 was considered statistically significant.
Results
MPS patient figures and utilization data from cardiology
Table 1 lists the MPS patient numbers of the particular survey,
the estimated total patient numbers after adjustment to the
NASHIP statistics and MPS per million population (pmp).
During the period under review, mean and median MPS
figures mildly increased but differ, which accounts for a large
percentage of centres with only a few studies. Since 2006 a
mild decrease in centres with <50 MPS/year (<1 MPS/week)
has been observed and, on the other hand, a mild increase in
centres with >1,000 MPS/(>4 MPS/day) since 2007. For the
first time, MPS studies pmp showed a slight increase from
2009 to 2012 and currently reach the 2007/2008 level.
A total of 108 centres delivered data in all six surveys.
They demonstrate an increase in MPS patients of 4.0 %
(50,392 to 52,400) from 2005 to 2012 (Fig. 1).
The number of angiographies, interventions and ratios are
presented in Table 2. In 2011, the angiography numbers
slightly declined for the first time since 1980, by 1.3 %.
Bypass surgery figures decreased and percutaneous translu-
minal coronary angioplasty (PTCA) figures increased over the
observation period. The total revascularization figures in-
creased and the angiography to revascularization ratio
remained constant. From 2005 to 2009, the angiography to
MPS ratio increased and the revascularization to MPS ratio
decreased. In 2012, both demonstrated opposite trends for the
first time.
Individual changes in referral behaviour and competitive
methods
In 2006, 2007 and 2012 the participants were asked to assess
their individual development ofMPS numbers and changes by
competitive methods. Their estimates are given in Table 3. In
2012 more than 50 % of the centres experienced no change or
even an increase in MPS numbers. The percentage of those
with decreasing MPS numbers was lowest in 2012. The
leading single competitor was MRI, followed by angiography
and stress echocardiography. CT still seemed to play a minor
role. The greatest competition, however, was not experienced
by one single but by several competitive imaging methods.
Protocols, radiopharmaceuticals and effective doses
The utilization frequency of typical study protocols is given in
Table 4 (upper half). Hybrid protocols were only questioned in
2005 and thereafter omitted due to their very low proportion.
In 2005, no splitting of 99mTc protocols into 1-day or 2-day
protocols occurred, and in all surveys there was no differen-
tiation of 99mTc radiopharmaceuticals (sestamibi or
tetrofosmin).
Table 1 MPS utilization and lo-
cal activity
a The adjustment by the NASHIP
(National Association of Statuto-
ry Health Insurance Physicians)
statistics revealed that about 50–
55 % of all MPS were evaluated
in every query. To obtain the total
MPS patient number the survey
numbers were multiplied by 2
2005 2006 2007 2008 2009 2012
MPS patients (survey) 112,136 108,939 114,374 99,879 98,253 105,941
Total MPS patientsa 224,272 217,878 228,748 199,758 196,506 211,882
MPS pmp 2,720 2,640 2,770 2,420 2,380 2,580
No. of centres 356 353 370 312 292 278
Mean MPS 315 309 309 320 336 381
Median MPS 160 144 141 147 163 179
< 50 MPS/year 18.5 % 28.6 % 25.4 % 26.9 % 23.3 % 20.9 %
> 1,000 MPS/year 7.6 % 8.5 % 7.6 % 8.7 % 8.6 % 10.4 %
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201Tl studies have been decreasing continuously since
2005. Their proportion reached only 5 % in 2012. 99mTc
MPS studies showed a mild increase in 2-day protocols. The
proportions of the other 99mTc protocols varied to some extent
over time, but remained on the same level.
Table 5 lists the administered radiopharmaceutical activi-
ties and Table 4 (lower half) the average effective dose range
of anMPS patient according to the utilization of the protocols.
The data document an average effective dose per patient of
7.4 mSv in 2012 and, due to the decreasing use of 201Tl, a mild
decline over the observation period of 7 % for the average
upper and 16 % for the average lower patient doses (Fig. 2).
Stress techniques
Table 6 shows the utilization of stress techniques. Dynamic
exercise stress was the most common stress test, but its share
continuously decreased. Adenosine represented the leading
pharmacological stress agent with a growing percentage.
Dipyridamole is not licensed as a MPS stressor in Germany
and can be applied only under certain circumstances. Thus, its
acceptance has decreased. Regadenoson was licensed in
Germany in 2011 and has been available since September
2011. Its share reached 8 % in 2012. All vasodilator stress
tests were increasingly combined with low-level exercise.
Dobutamine was only used to a very low extent.
Gated SPECT and segmental scoring
Gated SPECT is an important adjunct to myocardial perfusion
SPECT, but at the beginning of the surveys it showed only a
low penetration and acceptance (Table 7, upper half). Over
time, gated SPECT experienced a growing increase.
The percentage of centres performing a regular, an inter-
mediate or no quantification with scores is listed in Table 7
(lower half). This feature was queried for the first time in
2007. In 2012, more than 40 % of all centres did not apply
any segmental scoring at all. The percentage of centres with a
regular scoring was even lower, but slowly increased.
MPS referrals
Table 8 shows the referral structure of MPS. Ambulatory care
cardiologists represented the major referral group, followed
by ambulatory care internists and hospitals. In 2012, the
cardiologists’ percentage lay well over 50 %, whereas refer-
rals from internists and of inpatients declined. Referrals from
primary care physicians and others remained essentially un-
changed over the reporting period.
Attenuation correction
AC and the technique used were questioned in 2006 and 2009
(Table 9). Both inquiries revealed a low percentage of MPS
studies being performed with AC. Transmission source-based
ACwas used slightly more frequently than CT-based AC. The








2005 2006 2007 2008 2009 2012
Fig. 1 Numbers of MPS patients of the 108 centres participating in all
surveys from 2005 to 2012
Table 2 Angiographies, interventions and ratios
2005 2006 2007 2008 2009 2010 2011 2012
Angiography 772,137 806,533 832,420 851,517 864,858 881,514 870,282 a
Angiography pmp 9,370 9,800 10,130 10,380 10,400 10,690 10,630 a
Angiography/MPS 3.4 3.7 3.6 4.3 4.4 – – 4.1b
Revascularization (total) 338,300 355,552 363,054 365,777 368,661 381,865 383,953 a
PTCA 270,964 291,050 299,690 304,719 310,166 325,872 328,654 a
Bypass 67,336 64,502 63,364 61,058 58,495 55,993 55,299 a
Angiography/revascularization 2.3 2.3 2.3 2.3 2.3 2.3 2.3 a
Revascularization/MPS 0.66 0.61 0.63 0.55 0.53 – – 0.55b
a Data still unpublished at the time of writing
b The MPS 2012 numbers were related to cardiology data from 2011
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Diabetics, age of patients and indications
In 2007 the percentage of diabetics was surveyed. The pro-
portion of diabetics inMPS studies was found to be 21%. The
age structure of the MPS patients was recorded 1 year later.
The data revealed that 15 %were aged<50 years, 57 % 50–70
years and 28 % >70 years. In 2006, about 40 % of MPS
addressed the issue “suspected CAD”. No further differentia-
tion of indications occurred.
Discussion
This paper summarizes six surveys on MPS from 2005 to
2012, gives an overview of changes in recent years and
demonstrates the current state of MPS practice in Germany.
Furthermore, the data allow an estimation of average patient
doses from MPS and changes over time.
It should be noted that the surveys represent average and
routine use of MPS over a wide user spectrum and not exclu-
sively high-end users. The representativeness of the survey
was evaluated in relation to data submitted by the NASHIP,
which reimburses services of statutory outpatient care. In
relation to the NASHIP numbers, about 50–55 % of all MPS
were covered by each survey. The results of all surveys can be
regarded as representative. The derived total annual MPS
numbers tend to be slightly overestimated by <10 %. This
bias applies to all surveys, but does not affect the inter-survey
relationships.
The last European survey (reporting year 2007) was pub-
lished in 2012 and represented 258 European centres, of which
30 were German centres [17]. With data provided from 278–
370 centres, the Germany survey data are more comprehensive.
Representing about 20% of the European population, theymay
also reflect general European MPS practice and development.
The key issues of all six surveys are:
1. Between 2005 and 2012 the average annual utilization
rate was 2,590 MPS patients pmp, which was between a
moderate and a moderate-high utilization index according
to the subdivision by Vitola et al. [18]. Compared with the
European surveys, the annual utilization rate lies in the
upper half. Nevertheless, the German and the European
utilization numbers are in stark contrast to the USAwith
nearly 30,000 MPS pmp and an annual study number per
centre of 1,225 [8, 19]. The reasons are surely to be found
in the clear interdisciplinary division between cardiology
and nuclear medicine in Germany and the higher reim-
bursement in the USA. Only three ambulatory care cardi-
ologists practice nuclear cardiology imaging themselves
in Germany. Interestingly, these are high utilization cen-
tres with annual MPS numbers of >1,500.
Table 3 Per cent of survey participants with changes in referral behav-
iour by competitive methods
2006 2007 2012
Unknown 31 % 32 % 22 %
No change 45 % 40 % 29 %
More a a 27 %
Less 24 % 28 % 21 %
Less by
Cardiac MRI 30 % 23 % 22 %
Stress echo 18 % 16 % 12 %
Angiography 8 % 11 % 15 %
Cardiac CT 6 % 7 % 3 %
More than 1 method 38 % 43 % 32 %
Unknown a a 16 %
Percentages do not always total 100 because of rounding
a Not questioned
Table 4 Utilization of protocols and average effective patient doses
2005 2006 2007 2008 2009 2012 p value
Protocols 201Tl 20 % 15 % 17 % 12 % 11 % 5 % <0.001
99mTc stress only 15 % 14 % 12 % 15 % 13 % 16 % 0.006
99mTc 2-day 61 % 47 % 46 % 45 % 47 % 52 % <0.001
99mTc 1-day 22 % 23 % 26 % 28 % 25 % 0.03
99mTc rest 2 % 2 % 2 % 2 % 2 % 2 % n.s.
99mTc, 201Tl (hybrid) 2 % – – – – – –
Average effective doses Average max. patient dose (mSv) a 9.8 10.2 9.7 9.7 9.2 <0.001
Mean patient dose (mSv) a 8.2 8.7 8.1 8.1 7.4 <0.001
Average min. patient dose (mSv) a 6.6 7.1 6.5 6.5 5.6 <0.001
Percentages do not always total 100 because of rounding
a No calculation of doses; 1-day and 2-day protocols were not questioned
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2. CAD imaging and decision-making in Germany is clearly
morphology driven. The cardiology statistics reveal a
high angiography pmp rate which is 4 times higher on
average than the MPS pmp rate, and clearly above the
European angiography to MPS ratio of 2.5 [17]. A stable
angiography to revascularization ratio of 2.3 indicates that
far more than 50 % of all angiographies remain without
any interventional procedure. The estimate is in line with
other overviews which report a normal rate of 20–40 % in
angiographies and reveal a suboptimal preselection of
patients and obviously no essential change in the past
few years despite the results of the COURAGE trial [20,
21].
3. Other non-invasive imaging techniques are unlikely to
significantly impact the angiography to non-invasive im-
aging ratio. Numbers of stress echocardiograms in Ger-
many are not available. The same applies to CT angiog-
raphy and cardiac perfusion MRI, whose numbers are
certainly low because they are not yet reimbursed within
the statutory health insurance system.
4. TheMPS to revascularization ratio decreased from 0.66 in
2005 to 0.55 in 2012 (note: the MPS 2012 numbers were
related to cardiology data from 2011). It is lower than the
European ratio of 0.9 in 2007. The value of 0.55 reflects
the imbalance between functional and morphological im-
aging and suggests that many interventions are performed
without knowledge of myocardial perfusion/viability. The
German diagnosis-related group (DRG) system, which
reimburses cases and not single diagnostic steps, supports
this trend.
5. About 20–25% ofMPS studies were performed in centres
with less than 50MPS/year (<1MPS/week) and one tenth
in sites with more than 1,000 MPS/year (> 4 MPS/day).
Over the reporting period there was a slight trend towards
a concentration of MPS studies. This is a favourable
observation as competence increases with number of
studies. The low number of MPS patient centres should
be in the special focus of training and education. This was
one motivation to establish control panels by the medical
chambers in order to monitor quality standards according
to guidelines and radiation protection directives [1].
6. Centres participating in all surveys from 2005 to 2012
reported an increase in their MPS numbers of 4 % on
average. Only university hospitals experienced a decline
in their numbers, indicating a shift towards preclinical
diagnosis. It should be noted that the 108 centres in all
surveys are not exactly representative since they are likely
to represent a selection of more active and motivated
centres.
On the other hand, a mild increase could also be
noticed from 2009 to 2012, and more than 50 % of the
centres noticed no change or an increase in MPS imaging
in this period.
To summarize, several indicators support the statement
of a positive turnaround in MPS imaging.
7. The survey participants regarded MRI, angiography and
stress echocardiography as competitive methods. As stat-
ed above, the proportion of MRI in myocardial perfusion
imaging is estimated to be low because this service is not
yet reimbursed. Angiography showed a slight decline for
Table 5 Protocols, administered activity ranges and effective doses
Radiopharmaceutical Protocol DRLa Administered activity range Effective dose range
Average lower level Average upper level
(MBq) (MBq) (MBq) (mSv)
201Tl 75 75 75 16.5
99mTc-sestamibi or 99mTc-tetrofosmin Stress only 600 250 600 2.0–4.8
Rest only 600 250 600 2.3–5.4
1-day protocol 1,000 250 stress, 750 rest* 250 stress, 750 rest* 8.8
2-day protocol 1,200 250 stress, 250 rest 600 stress, 600 rest 4.3–10.2
*According to DRL no definition of lower and upper dosage levels








2006 2007 2008 2009 2012
mSv
Fig. 2 Average, maximal and minimal patient dose per MPS based on
lower and upper levels of administered activities (Table 5) and protocol
use from 2006 to 2012
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the first time in 2011. Together with the increase in
referrals from cardiologists, this may be another indicator
towards more non-invasive imaging. Utilization numbers
for the coming years will further clarify the developments
and evaluate the statement.
8. Procedural and technical issues
8.1. 99mTc radiopharmaceuticals (sestamibi and
tetrofosmin) are the dominating agents inMPS, with
a growing percentage over time. Rest-only studies
are very rare, indicating that viability imaging plays
a minor role in MPS. The percentage of stress-only
protocols is nearly constant and higher than the
proportion of 3 % in the USA in 2008 [19]. As
about 40 % of MPS are related to patients with
suspected CAD (2006 survey data), a higher amount
of stress-only studies could be expected. In the
setting of a normal stress study, an additional rest
study is not of additional benefit [22]. Thus, stress-
only protocols represent an effective measure to
substantially reduce radiation exposure and should
be the objective of future training and education.
The preferred use of 2-day 99mTcMPS protocols,
which allow the application of lower activities than
with 1-day protocols, is another issue to reduce
radiation exposure. The proportion is clearly higher
than in the ASNC survey (5.3 %) [9].
201Tl MPS studies significantly decreased from
20 % in 2005 to 5 % in 2012. Compared with the
ASNC survey (in 2011 15.6 % of protocols with
201Tl dual isotope and 0.7 % with 201Tl only), the
proportion in Germany is lower [9]. It is a clear
guideline statement that 99mTc radiopharmaceuticals
are preferred, and it is expected that the use of 201Tl
will further decline [23].
8.2. The surveys demonstrate a reduction in average
patient dose from 2006 to 2012 by changes in
protocol use primarily by the decline of 201Tl. The
shortage of 99mTc from 2008 to 2009 with a tem-
porary shift to more 201Tl imaging did not sustain-
ably affect average patient dose, which is clearly
below 10 mSv.
A single-centre analysis in Italy documented an
effective dose reduction with 99mTc-sestamibi im-
aging from 13.7 mSv to 5.7 mSv from 2002 to 2012
by weight adjustment of activities and new camera
technology together with dedicated reconstruction
algorithms [24]. Our survey dose data refer to
Table 6 Stress techniques in MPS
2005 2006 2007 2008 2009 2012 p value
Ergometry 78 % 73 % 73 % 69 % 69 % 61 % <0.001
Adenosine 21 % 14 % 18 % 20 % 23 % 24 % <0.001
Dipyridamole 10 % 9 % 9 % 8 % 5 % 0.038
Regadenoson 9 % –
Dobutamine 1 % 2 % 1 % 1 % 1 % 1 % n.s.
Adenosine+LLEa b 29 % 25 % 22 % 32 % 39 % n.s.
Dipyridamole+LLEa b 57 % 54 % 61 % 64 % 60 % n.s.
Regadenoson+LLEa 51 % –
Percentages do not always total 100 because of rounding
LLE low-level exercise
a Percentage of the respective vasodilator stress tests combined with LLE
b In 2005, data of adenosine and dipyridamole were not requested
Table 7 MPS acquisition as gated SPECT and centres with segmental scoring
2005 2006 2007 2008 2009 2012 p value
Gated SPECT At stress 32 % 39 % 43 % 42 % 55 % 73 % <0.001
At rest 36 % 42 % 46 % 46 % 55 % 70 % <0.001
At stress and rest 14 % 36 % 37 % 37 % 47 % 67 % <0.001
Centres with perfusion scoring Always 16 % 22 % 33 % 35 % <0.001
Intermediate 23 % 15 % 16 % 23 % 0.011
Never 61 % 62 % 52 % 41 % <0.001
Percentages do not always total 100 because of rounding
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average protocol use in a range of prescribed DRL.
They show a similar trend but as to be expected a
milder decline as they are not related to a single
centre.
The contribution of AC systems (CT based or
with transmission sources) is unlikely to affect our
dose data considerably as such systems are still rare
and of low additional dose [24].
To summarize, dose reduction is an ongoing
process in myocardial perfusion imaging; effective
steps are giving up 201Tl, more stress-only studies,
2-day studies instead of 1-day studies and new
technology.
8.3. Dynamic exercise stress is still the preferred form of
stress, but decreasing over the reporting period.
Pharmacological stress testing has increased, as
well as the combination of vasodilator stress and
low-level exercise. Regadenoson, available in Ger-
many since September 2011, already accounted for
8 % (ASNC survey 32.6 %) of stress tests in 2012
[8]. A further increase is to be expected.
One reason for the growing share of vasodilator
studies is the aging patient population with co-
morbidities making them unable to exercise ade-
quately. The 2008 data revealed that almost 30 % of
patients were aged >70 years and 21 % were dia-
betics (2007 data).
8.4. Gated SPECT experienced growing acceptance. In
2012 the greatest increase could be documented.
Starting with a proportion of only 35 % in 2005,
this constitutes favourable progress. A further in-
crease should be achievable considering that 95 %
of all studies are performed with 99mTc radiophar-
maceuticals and thus potential gated SPECT stud-
ies. ECG gating is not a reimbursed service in
Germany. This issue certainly contributes to the still
incomplete penetration.
8.5. All German surveys revealed an underuse of seg-
mental scoring of perfusion defects, with only slow-
ly growing acceptance. Guidelines clearly recom-
mend scoring of myocardial perfusion SPECT to
meet the full power of MPS for risk stratification
and therapeutic management [23, 25]. Thus, perfu-
sion scoring remains a target issue of training and
education in nuclear cardiology.
8.6. Until 2009, AC failed to become a standard in MPS
(proportion of less than 10 %). With a broader
dissemination of hybrid SPECT/CTcameras, a mild
increase is likely.
Conclusion
The six German surveys on MPS from 2005 to 2012 reflect
the competitive context of MPS in the field of mainly
morphology-based cardiac imaging. Nevertheless, the data
reveal a positive trend in MPS parallelled with a decrease in
average patient dose. Both issues and the procedural survey
results reflect good routine practice with adherence to the
current guidelines, the implementation of technical improve-
ments and success in training over the years. The German
experience of the past years may serve as a model for future
considerations in other countries.
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